Alnylam Pharmaceuticals: Wells Fargo cuts target price to $220 from $253
ALNY•Wells Fargo cut its target price for Alnylam Pharmaceuticals to $220 from $253.
Related News
IRadimed Q3 revenue beats estimates, narrows guidance
IRMD•
Viatris commences tender offer to acquire Pacira BioSciences
PCRX•
Hilton Grand Vacations enters accelerated share repurchase deal on Oct. 30, 2026
HGV•
Raymond James raises Republic Services target price to $252 from $235
RSG•
Hongli Group in talks to acquire 20% stake in Xell Energy
HLP•